Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH

Obeticholic acid (OCA) and elafibranor (ELA) are selective and potent agonists for the farnesoid X receptor (FXR) and dual peroxisome proliferator-activated receptor α/δ (PPAR-α/δ), respectively. Both agents have demonstrated clinical efficacy in nonalcoholic steatohepatitis (NASH). The present stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Roth, Jonathan D., Veidal, Sanne S., Fensholdt, Louise K. D., Rigbolt, Kristoffer T. G., Papazyan, Romeo, Nielsen, Jens Christian, Feigh, Michael, Vrang, Niels, Young, Mark, Jelsing, Jacob, Adorini, Luciano, Hansen, Henrik H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588626/
https://www.ncbi.nlm.nih.gov/pubmed/31227742
http://dx.doi.org/10.1038/s41598-019-45178-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588626/
https://www.ncbi.nlm.nih.gov/pubmed/31227742
http://dx.doi.org/10.1038/s41598-019-45178-z

Ejemplares similares